Investigator-Initiated Phase I/II Clinical Trial of Selinexor (KPT-330) and Pegylated Liposomal Doxorubicin for Relapsed and Refractory Multiple Myeloma
Status: Active, no longer recruiting
Phase of Trial: Phase I/II
Latest Information Update: 21 Feb 2019
Price : $35 *
At a glance
- Drugs Selinexor (Primary) ; Dexamethasone; Doxorubicin liposomal
- Indications Multiple myeloma
- Focus Adverse reactions; Therapeutic Use
- 28 Mar 2018 Planned End Date changed from 1 Jun 2019 to 1 Dec 2019.
- 28 Mar 2018 Planned primary completion date changed from 1 Jun 2018 to 1 Dec 2018.
- 12 Dec 2017 Results presented at the 59th Annual Meeting and Exposition of the American Society of Hematology.